Neurocrine Biosciences (NBIX) Other Working Capital Changes (2014 - 2026)

Neurocrine Biosciences (NBIX) has reported Other Working Capital Changes for 14 consecutive years, with -$500000.0 the latest figure, recorded in Q3 2025.

• For the quarter ending Q3 2025, Other Working Capital Changes changed N/A year-over-year to -$500000.0; the trailing twelve-month figure through Jun 2026 stood at -$500000.0 (down 138.46% YoY), and the FY2025 full-year result was $700000.0, up 600.0% from the prior year.
• Other Working Capital Changes declined to -$500000.0 in Q3 2025 per NBIX's latest filing, from $500000.0 in the prior quarter.
• Across five years, Other Working Capital Changes topped out at $50.9 million in Q3 2023 and bottomed at -$78.8 million in Q2 2026.
• Historically, Other Working Capital Changes has averaged $5.4 million across 5 years, with a median of $14.6 million in 2022.
• The widest YoY moves for Other Working Capital Changes: up 3500.0% in 2024, down 1600.0% in 2024.
• Over 5 years, Other Working Capital Changes stood at -$10.7 million in 2021, then surged by 86.92% to -$1.4 million in 2022, then soared by 192.86% to $1.3 million in 2023, then slumped by 92.31% to $100000.0 in 2024, then slumped by 600.0% to -$500000.0 in 2025.
• According to Business Quant data, Other Working Capital Changes over the past three periods registered -$500000.0, $500000.0, and $700000.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.